{"id":40095,"date":"2026-11-19T11:17:00","date_gmt":"2026-11-19T16:17:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=40095"},"modified":"2026-11-07T14:02:47","modified_gmt":"2026-11-07T19:02:47","slug":"why-your-competitors-failed-patent-challenge-is-the-best-market-intelligence-youre-not-reading","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/why-your-competitors-failed-patent-challenge-is-the-best-market-intelligence-youre-not-reading\/","title":{"rendered":"Why Your Competitor&#8217;s Failed Patent Challenge Is the Best Market Intelligence You&#8217;re Not Reading"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"572\" src=\"https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2026\/11\/image-9.png\" alt=\"\" class=\"wp-image-40098\" srcset=\"https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2026\/11\/image-9.png 1024w, https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2026\/11\/image-9-300x168.png 300w, https:\/\/www.drugpatentwatch.com\/blog\/wp-content\/uploads\/2026\/11\/image-9-768x429.png 768w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">On August 5, 2020, a federal judge in Delaware held that two patents on Eliquis (apixaban) were valid and infringed by generic challengers. <a href=\"#ref1\">[1]<\/a> Bristol-Myers Squibb shares rose about 5.3 percent after the ruling. <a href=\"#ref2\">[2]<\/a> The challengers lost the case. They also created a public record that moved the expected generic entry date, set the meaning of the claims, and showed how one challenger controls the particle size of its tablets.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Most competitive intelligence teams read the press release about a ruling and stop. This article argues that the court record deserves a longer read. It reviews four cases: Eliquis, Nuplazid, Entresto, and Cabometyx. It also uses three published datasets on how often patent challenges fail. Every date and count comes from a court opinion, a regulatory filing, a company release, or a published study. Calculated figures carry the label &#8220;analysis.&#8221;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The word &#8220;competitor&#8221; in the title has two meanings. It can mean a generic or biosimilar company that lost a challenge against a product like yours. It can mean a company in your own therapeutic class that watches a rival defend its patents. Investors and business development teams read the same record for a third reason: they price both sides of the dispute.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Short Answer: A Failed Patent Challenge Is a Court-Tested Map of Your Competitor&#8217;s Position<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A failed patent challenge does four things that a press release does not. It shows which patents a court has tested. It shows which arguments failed. It shows what the claims mean in the court&#8217;s words. It shows which dates now govern the market. A reader who extracts all four items has a better forecast than a reader who records only &#8220;patent upheld.&#8221;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>The Five Findings That Matter<\/strong><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Bristol-Myers Squibb&#8217;s 2020 annual report gave two possible launch dates for settled Eliquis generics. The date was April 1, 2028 if the Delaware rulings held on both patents. The date was November 21, 2026 if the formulation patent failed. The gap is 497 days (analysis). <a href=\"#ref3\">[3]<\/a><\/li>\n\n\n\n<li>Acadia says its composition of matter patent on Nuplazid (pimavanserin) expires in 2030. It says four patents on the 34 mg capsule expire in 2038. The formulation patents outlast the compound patent by eight calendar years (analysis). <a href=\"#ref4\">[4]<\/a><\/li>\n\n\n\n<li>In a study of 328 final ANDA decisions, courts invalidated 142 of 546 litigated Orange Book patents that received a validity ruling, about 26 percent. <a href=\"#ref5\">[5]<\/a> By subtraction, 404 patents, or 74 percent, were not invalidated (analysis).<\/li>\n\n\n\n<li>On January 10, 2025, the Federal Circuit rejected each invalidity ground it reviewed against Entresto&#8217;s &#8216;659 patent. <a href=\"#ref6\">[6]<\/a> The patent expired on January 15, 2025, and pediatric exclusivity extended it to July 15, 2025. <a href=\"#ref7\">[7]<\/a><\/li>\n\n\n\n<li>On August 31, 2026, Exelixis reported that the Federal Circuit upheld three cabozantinib patents against MSN. The earliest MSN launch date is January 15, 2030. A fourth patent, which expires in February 2032, goes to trial in November 2026. <a href=\"#ref8\">[8]<\/a><\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Each finding stands alone. The sections below give the source and the method for each one.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Methodology: What I Analyzed and What I Left Out<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Data and Time Period<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">I analyzed four ANDA matters decided between 2020 and 2026. For each matter I used at least one primary document: a court opinion, an SEC filing, or a company release. I added trade press only for context, such as share price moves and settlement counts. I also used three published datasets: a 2002 FTC statement, a 2022 law review study by S. Sean Tu and Mark Lemley, and a 2019 analysis of Orange Book patents at the Patent Trial and Appeal Board.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Selection, Duplicates, and Calculations<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A record counted as a failed challenge if a court upheld at least one asserted patent against a validity challenge from an ANDA filer. I counted each patent once. Eliquis therefore contributes two patents, and Cabometyx contributes four. I calculated day counts with date arithmetic in Python. I took percentages from published counts. Every calculated figure in this article is labeled as analysis.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Limits of This Analysis<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Four cases are a purposive sample. They do not support a statistical claim about all pharmaceutical litigation. Company releases are advocacy documents, so I used them for dates and holdings and checked them against court records where I could. Patent expiration dates can change with term extensions or terminal disclaimers. Settlement terms are mostly confidential. A 10-K shows the company&#8217;s view on the filing date, not the final outcome.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What Is a Failed Patent Challenge? Definitions and a Four-Type Taxonomy<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Paragraph IV Challenge, Inter Partes Review, and the Word &#8220;Failed&#8221;<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A Paragraph IV challenge happens when an ANDA filer tells the brand company that a listed patent is invalid or not infringed. The brand company can sue, and the court then decides. An inter partes review (IPR) is a separate challenge. It takes place at the Patent Trial and Appeal Board of the USPTO. A challenge &#8220;fails&#8221; in this article when the patent, or at least one asserted claim, survives.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Four Ways a Patent Challenge Fails (Original Framework)<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The taxonomy below is my own. It is not an established industry classification. I built it to separate failures that carry different information.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Type 1: Validity-Merits Failure<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The court weighs the invalidity theory and rejects it. In the Eliquis case, the defendants argued that claims of the &#8216;208 patent were improperly dependent, not enabled, and lacked written description. The court upheld the claims. <a href=\"#ref1\">[1]<\/a> This type gives the most information about which arguments do not work against a given claim.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Type 2: Claim-Construction Failure<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The court adopts the patent owner&#8217;s reading of a claim term. In Eliquis, Sigmapharm argued that a ring-substitution limit excluded apixaban. The court read the phrase &#8220;substituted with [N] R&#8221; to mean &#8220;replaced with [N] R&#8221; and rejected that argument. <a href=\"#ref1\">[1]<\/a> The Federal Circuit adopted the district court&#8217;s constructions. <a href=\"#ref9\">[9]<\/a> This type defines the boundary that every later challenger must cross.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Type 3: Procedural Failure<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The challenge never reaches the merits. In IPR, this means the Board declines to institute review. Through fiscal year 2018, the Board instituted 66 percent of Orange Book petitions. <a href=\"#ref10\">[10]<\/a> The remaining 34 percent were not instituted on any ground (analysis). This type says little about the patent. It says more about timing and forum.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Type 4: Mooted Failure<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">An event makes the challenge irrelevant. In the Cabometyx appeal, the court dismissed the appeal on the &#8216;349 patent as moot. <a href=\"#ref8\">[8]<\/a> In the Entresto case, the &#8216;659 patent expired during the dispute. <a href=\"#ref7\">[7]<\/a> This type tells you that the live question moved to another patent.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Glossary: Eight Terms Used in This Analysis<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Term<\/th><th>Definition<\/th><\/tr><\/thead><tbody><tr><td>Orange Book<\/td><td>The FDA list of approved drug products, with the patents that brand companies submit for them.<\/td><\/tr><tr><td>ANDA<\/td><td>Abbreviated New Drug Application. A generic company files it to seek approval of a copy of a brand drug.<\/td><\/tr><tr><td>Claim construction<\/td><td>The court&#8217;s decision on what a claim term means.<\/td><\/tr><tr><td>Written description<\/td><td>The rule that a patent must show that the inventor had the claimed invention at filing.<\/td><\/tr><tr><td>Enablement<\/td><td>The rule that a patent must teach a skilled person how to make and use the claimed invention.<\/td><\/tr><tr><td>Obviousness<\/td><td>A ground of invalidity. It applies when the claimed invention would have been obvious to a skilled person in view of the prior art.<\/td><\/tr><tr><td>Pediatric exclusivity<\/td><td>A six-month extension that attaches to existing protection. In Entresto, the date moved from January 15, 2025 to July 15, 2025. <a href=\"#ref7\">[7]<\/a><\/td><\/tr><tr><td>D90<\/td><td>A particle-size measure. It is the diameter below which 90 percent of the particles fall.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How Often Do Patent Challenges Fail? What the Published Data Shows<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Failure is common, but the rate depends on the measure. Three published datasets give three different answers. Table 1 lists them side by side.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Source<\/th><th>Period or sample<\/th><th>Measure<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td>FTC testimony, Oct. 9, 2002 <a href=\"#ref11\">[11]<\/a><\/td><td>Litigation status as of June 1, 2002<\/td><td>Share of decided infringement cases that generic applicants won<\/td><td>73 percent<\/td><\/tr><tr><td>Tu and Lemley, 2022 <a href=\"#ref5\">[5]<\/a><\/td><td>328 ANDA cases with final decisions; 632 patents; cases pending Jan. 1, 2009 to Jan. 15, 2021<\/td><td>Share of litigated Orange Book patents invalidated (142 of 546 with a validity ruling)<\/td><td>About 26 percent<\/td><\/tr><tr><td>Schwarz and Fishwick, 2019 <a href=\"#ref10\">[10]<\/a><\/td><td>PTAB inception through Sept. 30, 2018<\/td><td>Share of Orange Book IPR petitions instituted<\/td><td>66 percent (74 percent for all IPRs)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>FTC, 2002: Generic Applicants Prevailed in 73 Percent of Decided Cases<\/strong><\/h3>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">In its 2002 study of Hatch-Waxman litigation, the Federal Trade Commission found that generic applicants prevailed in 73 percent of patent infringement cases in which a court had ruled. <a href=\"#ref11\">[11]<\/a><\/p>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\">The FTC also reported that brand companies sued the first generic applicant for 72 percent of the drug products it examined. <a href=\"#ref11\">[11]<\/a> The figure measures case outcomes, not patent validity. A generic win can come from non-infringement as well as invalidity. The data are more than two decades old.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Tu and Lemley, 2022: Courts Invalidated 26 Percent of Litigated Orange Book Patents<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Tu and Lemley studied 328 federal district court cases with final decisions. The cases covered 632 patents. <a href=\"#ref5\">[5]<\/a> The authors report that about 26 percent of litigated Orange Book patents were invalidated, 142 of 546 patents with a validity ruling. <a href=\"#ref5\">[5]<\/a> In the same study, most invalidations rested on obviousness. More than a quarter rested on Section 112. <a href=\"#ref5\">[5]<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Primary Patents and Secondary Patents Compare Differently<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The authors split patents into primary patents, which cover new chemical entities, and secondary patents, which cover items such as formulations, dissolution profiles, and new uses. Courts invalidated 15 percent of primary patents and 27 percent of secondary patents. <a href=\"#ref5\">[5]<\/a> Secondary patents made up 89 percent of the valid patents and 94 percent of the invalid patents in the sample. <a href=\"#ref5\">[5]<\/a> Primary patents survived more often, but secondary patents carry most of the volume.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>PTAB: Orange Book Patents in Inter Partes Review Through Fiscal Year 2018<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Christina Schwarz and Laura Fishwick analyzed Orange Book IPR petitions from the start of the Board through September 30, 2018. By patent type, the Board instituted 66 percent of compound petitions, 61 percent of formulation petitions, and 72 percent of method-of-treatment petitions. <a href=\"#ref10\">[10]<\/a> At least one instituted claim survived in 59 percent of Orange Book cases. <a href=\"#ref10\">[10]<\/a> The Orange Book petition count fell from 132 in fiscal year 2015 to 67 in fiscal year 2018. <a href=\"#ref10\">[10]<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Why the Three Numbers Disagree<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The three figures measure different things in different forums and years. The FTC counts case wins. Tu and Lemley count patent-level validity rulings. The PTAB figures count institution decisions and claim survival. Analysis: the Tu and Lemley result means that, in decided cases, 74 percent of litigated Orange Book patents survived a validity ruling. A failed challenge is therefore the usual result in that sample. The useful signal sits in the details of each failure, not in the fact of failure.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">One more limit applies. Cases that settle do not produce opinions. The opinions you can read come from cases where both sides chose to go to judgment. That selection effect is part of what you read.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Five Layers of Intelligence Inside a Failed Challenge (Original Framework)<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">I use five layers to read a failed challenge. The layers are my own framework. Each layer answers a different business question.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Layer 1: The Date Layer<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ask which dates the ruling set or removed. Bristol-Myers Squibb&#8217;s FY2020 annual report listed three outcomes for Eliquis. If the Delaware decision held for both patents, &#8220;the permitted date of launch for the settled generic companies under these patents is April 1, 2028.&#8221; If the formulation patent was held invalid or not infringed, generic companies could launch on November 21, 2026. If both patents failed, generic companies &#8220;could launch immediately.&#8221; <a href=\"#ref3\">[3]<\/a> The challengers&#8217; loss removed two of the three branches.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Layer 2: The Claim Layer<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ask what the claims now mean. Claim 12 of the &#8216;945 Eliquis patent requires crystalline apixaban particles with a D90 equal to or less than about 89 micrometers. It also requires that at least 77 weight percent dissolve within 30 minutes under stated test conditions. <a href=\"#ref1\">[1]<\/a> The Federal Circuit adopted the district court&#8217;s constructions of the D90 term and the term &#8220;crystalline apixaban particles.&#8221; <a href=\"#ref9\">[9]<\/a> A later challenger now works against fixed definitions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Layer 3: The Prior-Art Layer<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ask which prior art and which reasoning failed. The answer shows the arguments a court has already rejected.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Example: Eliquis Formulation Claims<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">On the &#8216;945 patent, the district court found that the prior art gave no motivation to reach the target dissolution rate or to select a D90 of 89 micrometers or less. <a href=\"#ref1\">[1]<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Example: Entresto Combination Claims<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">On the Entresto &#8216;659 patent, the Federal Circuit noted that sacubitril was one of more than 100 known NEP inhibitors in 2002. It had never been given to humans or animals, and clinical results for other NEP inhibitors were discouraging. The court agreed that MSN&#8217;s obviousness theories used hindsight. <a href=\"#ref6\">[6]<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Analysis: Tu and Lemley found that examiners had cited only 44 of the 383 references (11 percent) that courts used to invalidate patents on obviousness grounds. <a href=\"#ref5\">[5]<\/a> When a challenger loses with art that already sat in the prosecution record, little new art may remain for the next challenger. When a challenger loses with new art, the court&#8217;s reasoning still maps the next argument.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Layer 4: The Product and Process Layer<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ask what the opinion says about the challenger&#8217;s own product. In Eliquis, Sigmapharm argued that Bristol-Myers Squibb had not proved the D90 limit. The district court held that precise measurements were unnecessary because Sigmapharm&#8217;s manufacturing process made particles larger than 89 micrometers impossible. <a href=\"#ref1\">[1]<\/a> The court found that the other ANDA products also met the D90 limit. <a href=\"#ref1\">[1]<\/a> A public opinion now links a manufacturing process to a claim limit.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Layer 5: The Portfolio Layer<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ask which patent in the estate carries the commercial weight. A failed challenge often shows that the patent most people cite is not the patent that sets the date. The Nuplazid case in a later section shows this clearly.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Eliquis vs. Generic Challengers: How Two Failed Challenges Moved Generic Entry From 2026 to 2028<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Eliquis is a useful case because the company disclosed both the pre-ruling and post-ruling dates in public filings. Bristol-Myers Squibb reported global Eliquis sales of $9.17 billion in 2020, a 16 percent increase from 2019. <a href=\"#ref12\">[12]<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Eliquis Patent Timeline, 2020 to 2028<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Date<\/th><th>Event<\/th><th>Source<\/th><\/tr><\/thead><tbody><tr><td>2019<\/td><td>Eliquis sales of $7.9 billion; FDA approved generic versions from Mylan and Micro Labs, which later settled<\/td><td><a href=\"#ref2\">[2]<\/a><\/td><\/tr><tr><td>Aug. 5, 2020<\/td><td>D. Del. (Judge Stark) upholds the &#8216;208 compound patent and the &#8216;945 formulation patent after a nine-day bench trial; opinion at 477 F. Supp. 3d 306<\/td><td><a href=\"#ref1\">[1]<\/a><\/td><\/tr><tr><td>Sept. 3, 2021<\/td><td>Federal Circuit affirms in full (Nos. 2020-2229, 2020-2252, 2020-2258)<\/td><td><a href=\"#ref9\">[9]<\/a><\/td><\/tr><tr><td>Sept. 2021<\/td><td>Trade press reports April 1, 2028 as the expected end of U.S. exclusivity<\/td><td><a href=\"#ref12\">[12]<\/a><\/td><\/tr><tr><td>Apr. 1, 2028<\/td><td>Permitted launch date for settled generic companies if the rulings stand<\/td><td><a href=\"#ref3\">[3]<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Analysis: the Federal Circuit decided the appeal 394 days after the district court ruling.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What Happened to the Scenario Tree<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Before the ruling, the annual report described three branches. Table 3 shows them.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Outcome on appeal<\/th><th>Generic launch date (settled companies)<\/th><th>Status after Sept. 3, 2021<\/th><\/tr><\/thead><tbody><tr><td>Both patents upheld<\/td><td>April 1, 2028<\/td><td>Occurred at the Federal Circuit<\/td><\/tr><tr><td>Formulation patent invalid or not infringed<\/td><td>November 21, 2026<\/td><td>Removed<\/td><\/tr><tr><td>Both patents invalid or not infringed<\/td><td>Immediately on adverse decision<\/td><td>Removed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The sources for Table 3 are the annual report <a href=\"#ref3\">[3]<\/a> and the Federal Circuit opinion. <a href=\"#ref9\">[9]<\/a> Analysis: the gap between the first and second branches is 497 days, or about 16.3 months. In August 2020, trade press reported that the companies expected generic entry &#8220;after 2026 but before 2031&#8221; subject to appeals. <a href=\"#ref2\">[2]<\/a> The court record narrowed that range to a single date.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>What the Market Priced<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Bristol-Myers Squibb shares settled about 5.3 percent higher after the district ruling. Pfizer shares rose about 1.4 percent. <a href=\"#ref2\">[2]<\/a> Eliquis accounted for 23 percent of Bristol-Myers Squibb revenue in the first six months of 2020. <a href=\"#ref2\">[2]<\/a> The asymmetry in the share move fits the revenue concentration (analysis).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How Settlement Dates Can Follow a Litigated Outcome<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Bristol-Myers Squibb settled with some generic filers before the August 2020 ruling and litigated against three. <a href=\"#ref2\">[2]<\/a> Trade press at the time reported that the settlements, with Mylan and Micro Labs, delayed their launches to at least 2026. It also reported that no financial terms were disclosed. <a href=\"#ref2\">[2]<\/a> The annual report shows that the settled companies&#8217; permitted launch date depended on how the litigation against the others ended: April 1, 2028 if both patents held, and November 21, 2026 if the formulation patent failed. <a href=\"#ref3\">[3]<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Analysis: a settled competitor&#8217;s date can be tied to a rival&#8217;s court result. A failed challenge by one filer can therefore set the entry date of a different filer that never went to trial. A forecast that lists only the litigants misses the settled companies that sit behind them.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What the &#8216;945 Claim Construction Tells Generic Developers<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The claim limits are numeric. A formulation team can read them as a design specification. It can also read the opinion to see how the court dealt with process evidence. The court tied particle size to the manufacturing process and did not require measurements. <a href=\"#ref1\">[1]<\/a> A developer who wants a different outcome needs a process that does not cap particle size below the limit, and needs evidence that proves it. This is analysis, not legal advice.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Nuplazid: What Happens When Failed Challenges Show Which Patent Carries the Date<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Nuplazid shows the portfolio layer. Acadia&#8217;s FY2025 annual report describes patents in tiers by expiration year. <a href=\"#ref4\">[4]<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Nuplazid Patent Tiers by Expiration Year<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Patent group<\/th><th>Expiration<\/th><th>Source<\/th><\/tr><\/thead><tbody><tr><td>Polymorph and approved-use patents<\/td><td>Between 2026 and 2028<\/td><td><a href=\"#ref4\">[4]<\/a><\/td><\/tr><tr><td>Composition of matter patent (pimavanserin and salts)<\/td><td>2030, including a patent term extension<\/td><td><a href=\"#ref4\">[4]<\/a><\/td><\/tr><tr><td>Two method-of-use patents, 10 mg tablet<\/td><td>2037<\/td><td><a href=\"#ref4\">[4]<\/a><\/td><\/tr><tr><td>Four patents, 34 mg capsule formulation<\/td><td>2038<\/td><td><a href=\"#ref4\">[4]<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Two court rulings in 2025 tested these tiers. On May 16, 2025, the Delaware district court ruled for Acadia on infringement and validity of the &#8216;721 formulation patent against Aurobindo and other ANDA filers. Acadia says this provides protection for the 34 mg capsule into 2038. <a href=\"#ref13\">[13]<\/a> On June 9, 2025, Acadia reported that the Federal Circuit affirmed a December 2023 Delaware decision that upheld the &#8216;740 composition of matter patent, which provides protection into 2030. <a href=\"#ref14\">[14]<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Analysis: the formulation patents run eight calendar years past the compound patent (2038 minus 2030). A model that stops at the compound patent date misses most of the exclusivity period that Acadia defends in court. The failed challenges to the 2038 patent matter more commercially than the failed challenge to the 2030 patent.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>The Allergan v. MSN Rule in the Acadia Appeal<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Acadia says the Federal Circuit applied its earlier decision in Allergan USA, Inc. v. MSN Laboratories. Acadia describes the rule this way: &#8220;a first filed, first-issued, later-expiring claim cannot be invalidated&#8221; by a later-filed, later-issued, earlier-expiring reference claim with a common priority date. <a href=\"#ref14\">[14]<\/a> This is the company&#8217;s description of the holding. Read the opinion before you rely on the rule.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Entresto: Why a Failed Validity Challenge Did Not Decide the Launch Date<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Entresto (sacubitril\/valsartan) shows the limit of the date layer. A challenger can lose every validity argument on one patent and still reach the market, because the patent expires or another patent fails to block it. The Federal Circuit opinion reports that Entresto&#8217;s U.S. sales exceeded $3 billion in 2023. <a href=\"#ref6\">[6]<\/a> Novartis reported more than $5.6 billion in Entresto sales in the first nine months of 2024, about 19 percent of its revenue for that period. <a href=\"#ref15\">[15]<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What the Federal Circuit Held on the &#8216;659 Patent<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The case was In re Entresto, Nos. 2023-2218, 2023-2220, and 2023-2221. Judge Lourie wrote the opinion for a panel that included Judges Prost and Reyna. The decision issued on January 10, 2025. <a href=\"#ref6\">[6]<\/a> The &#8216;659 patent had a priority date of January 17, 2002 and expired on January 15, 2025 because of a patent term extension. Claim 1 recites valsartan, a NEP inhibitor, and a carrier, &#8220;administered in combination in about a 1:1 ratio.&#8221; <a href=\"#ref6\">[6]<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Written Description<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The district court had held claims 1 to 4 invalid for lack of written description after a July 7, 2023 decision. The Federal Circuit reversed. It held that the claims cover the combination, not the later-discovered complex, and that the district court conflated patentability with infringement. The court said that the invention, for written description purposes, is whatever the patent now claims. <a href=\"#ref6\">[6]<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Enablement and Obviousness<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The district court had found the claims not invalid for obviousness and enablement. The Federal Circuit affirmed both points. It held that a challenger cannot use later-existing state of the art to invalidate a patent that was enabled for what it claimed at filing. <a href=\"#ref6\">[6]<\/a> Analysis: this reasoning applies to any combination patent where a later technical discovery changes how the product is described.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>The &#8216;918 Patent and the Preliminary Injunction Denial<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The second Entresto patent is the &#8216;918 patent, which covers an amorphous solid form and expires in November 2026. <a href=\"#ref15\">[15]<\/a> Novartis argued that MSN&#8217;s generic contains small amounts of crystalline forms of the active ingredients that infringe the patent. <a href=\"#ref15\">[15]<\/a> FDA approved MSN&#8217;s generic on July 24, 2024. <a href=\"#ref16\">[16]<\/a> In August 2024, Judge Andrews denied Novartis a preliminary injunction. He wrote: &#8220;Novartis bears the burden of proof, both on infringement and on showing likelihood of success.&#8221; <a href=\"#ref16\">[16]<\/a> The Federal Circuit upheld that denial in December 2024. <a href=\"#ref15\">[15]<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Novartis asked the court to bar MSN&#8217;s launch until after November 9, 2026. <a href=\"#ref7\">[7]<\/a> Analysis: the window from July 16, 2025 to that date is 481 days. The Entresto record shows two different failures with two different commercial results. MSN lost on validity of the &#8216;659 patent, and that loss mattered only until pediatric exclusivity ended in July 2025. Novartis then lost its request for an injunction on the &#8216;918 patent, and that loss removed one barrier to a launch before November 2026.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Entresto Timeline, 2023 to 2026<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Date<\/th><th>Event<\/th><th>Source<\/th><\/tr><\/thead><tbody><tr><td>July 7, 2023<\/td><td>District court decides: &#8216;659 claims not obvious or non-enabled, but invalid for lack of written description<\/td><td><a href=\"#ref6\">[6]<\/a><\/td><\/tr><tr><td>July 24, 2024<\/td><td>FDA approves MSN&#8217;s generic<\/td><td><a href=\"#ref16\">[16]<\/a><\/td><\/tr><tr><td>Aug. 2024<\/td><td>District court denies Novartis a preliminary injunction on the &#8216;918 patent<\/td><td><a href=\"#ref15\">[15]<\/a><\/td><\/tr><tr><td>Dec. 2024<\/td><td>Federal Circuit upholds the injunction denial<\/td><td><a href=\"#ref15\">[15]<\/a><\/td><\/tr><tr><td>Jan. 10, 2025<\/td><td>Federal Circuit reverses written-description invalidity and affirms the other rulings on the &#8216;659 patent<\/td><td><a href=\"#ref6\">[6]<\/a><\/td><\/tr><tr><td>Jan. 15, 2025<\/td><td>&#8216;659 patent expires, with the patent term extension<\/td><td><a href=\"#ref6\">[6]<\/a><\/td><\/tr><tr><td>Apr. 2025<\/td><td>District court orders FDA to set MSN&#8217;s approval date no earlier than July 16, 2025<\/td><td><a href=\"#ref7\">[7]<\/a><\/td><\/tr><tr><td>June 2025<\/td><td>Novartis and MSN settle the &#8216;659 dispute<\/td><td><a href=\"#ref7\">[7]<\/a><\/td><\/tr><tr><td>July 15, 2025<\/td><td>Pediatric exclusivity ends on the &#8216;659 patent<\/td><td><a href=\"#ref7\">[7]<\/a><\/td><\/tr><tr><td>Nov. 2026<\/td><td>&#8216;918 patent expires<\/td><td><a href=\"#ref15\">[15]<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Analysis: the district court decision and the Federal Circuit ruling on the &#8216;659 patent are 553 days apart.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Cabometyx: Exelixis v. MSN and the Second Trial<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Cabometyx case is the most recent of the four. Exelixis announced on August 31, 2026 that the Federal Circuit, in Appeal No. 25-1236, had affirmed a key portion of the 2024 judgment of the District of Delaware in Civil Action No. 22-00228. <a href=\"#ref8\">[8]<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>The Three Patents Upheld<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The court affirmed that three patents are not invalid. These are the &#8216;439 patent on the crystalline malate salt, the &#8216;440 patent on pharmaceutical compositions, and the &#8216;015 patent on methods of treatment. <a href=\"#ref8\">[8]<\/a> The company states that the earliest MSN may launch its proposed generic in the United States is January 15, 2030, &#8220;subject to any additional appeals or regulatory exclusivity.&#8221; <a href=\"#ref8\">[8]<\/a> Analysis: that date is 1,233 days after the release date, or about 3.4 years.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>The Patent Still in Trial<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The court dismissed the appeal on the &#8216;349 low-impurity formulation patent as moot. A newer patent, the &#8216;039 low-impurity formulation patent, expires in February 2032 and has a trial set for November 2026. <a href=\"#ref8\">[8]<\/a> The release says MSN&#8217;s launch also depends on the outcome of that trial. Exelixis states that the ruling &#8220;does not impact the broader strength or integrity of the cabozantinib patent estate.&#8221; <a href=\"#ref8\">[8]<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Analysis: the time between the January 2030 date and the February 2032 expiration is about two years. A reader who stops at &#8220;three patents upheld&#8221; misses that a fourth patent controls the later window.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>One Challenger in Two Cases: What MSN&#8217;s Record Shows<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MSN Laboratories appears as the challenger in two of the four matters. It was the appellee in Entresto. <a href=\"#ref6\">[6]<\/a> It is the defendant in the Cabometyx case. <a href=\"#ref8\">[8]<\/a> The pattern is visible only when you read the cases together.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Patent(s) at issue<\/th><th>Result for MSN<\/th><th>Source<\/th><\/tr><\/thead><tbody><tr><td>Entresto<\/td><td>&#8216;659 (combination), &#8216;918 (amorphous solid form)<\/td><td>Lost on the &#8216;659 validity grounds reviewed; Novartis was denied an injunction on &#8216;918; FDA approved MSN&#8217;s generic July 24, 2024<\/td><td><a href=\"#ref6\">[6]<\/a> <a href=\"#ref16\">[16]<\/a><\/td><\/tr><tr><td>Cabometyx<\/td><td>&#8216;439, &#8216;440, &#8216;015 upheld; &#8216;349 moot; &#8216;039 in trial<\/td><td>Three patents upheld; earliest launch Jan. 15, 2030<\/td><td><a href=\"#ref8\">[8]<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Analysis: a filer that litigates to judgment on several drugs shows how it chooses its fights. The Entresto record also shows that losing on validity did not prevent FDA approval of MSN&#8217;s generic. <a href=\"#ref16\">[16]<\/a> Approval and patent clearance are separate gates. A team that tracks one filer across cases sees its pattern of arguments, not only its results.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Four Cases Compared: Dates, Patents, and Gaps<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Patents upheld<\/th><th>Challenger(s)<\/th><th>Decision<\/th><th>Date effect<\/th><th>Source<\/th><\/tr><\/thead><tbody><tr><td>Eliquis (apixaban)<\/td><td>&#8216;208 (compound), &#8216;945 (formulation)<\/td><td>Sigmapharm, Sunshine Lake, HEC Pharm USA, Unichem<\/td><td>D. Del. Aug. 5, 2020; Fed. Cir. Sept. 3, 2021<\/td><td>Apr. 1, 2028 for settled generics, versus Nov. 21, 2026 if the formulation patent had failed<\/td><td><a href=\"#ref3\">[3]<\/a> <a href=\"#ref9\">[9]<\/a><\/td><\/tr><tr><td>Nuplazid (pimavanserin)<\/td><td>&#8216;740 (compound), &#8216;721 (34 mg capsule formulation)<\/td><td>ANDA filers (&#8216;740); Aurobindo and other ANDA filers (&#8216;721)<\/td><td>D. Del. May 16, 2025 (&#8216;721); Fed. Cir. June 2025 (&#8216;740)<\/td><td>Protection into 2030 (&#8216;740) and into 2038 (&#8216;721)<\/td><td><a href=\"#ref13\">[13]<\/a> <a href=\"#ref14\">[14]<\/a><\/td><\/tr><tr><td>Entresto (sacubitril\/valsartan)<\/td><td>&#8216;659 (combination)<\/td><td>MSN<\/td><td>Fed. Cir. Jan. 10, 2025<\/td><td>Expiry Jan. 15, 2025; pediatric exclusivity to July 15, 2025<\/td><td><a href=\"#ref6\">[6]<\/a> <a href=\"#ref7\">[7]<\/a><\/td><\/tr><tr><td>Cabometyx (cabozantinib)<\/td><td>&#8216;439 (salt), &#8216;440 (compositions), &#8216;015 (methods)<\/td><td>MSN<\/td><td>Fed. Cir. announced Aug. 31, 2026<\/td><td>Earliest MSN launch Jan. 15, 2030; &#8216;039 trial Nov. 2026<\/td><td><a href=\"#ref8\">[8]<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Table 7 lists the calculated gaps. These are analysis. They are not reported statistics.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Case<\/th><th>Gap<\/th><th>Start date<\/th><th>End date<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td>Eliquis<\/td><td>Scenario difference<\/td><td>Nov. 21, 2026<\/td><td>Apr. 1, 2028<\/td><td>497 days (about 16.3 months)<\/td><\/tr><tr><td>Eliquis<\/td><td>Appeal duration<\/td><td>Aug. 5, 2020<\/td><td>Sept. 3, 2021<\/td><td>394 days<\/td><\/tr><tr><td>Nuplazid<\/td><td>Formulation versus compound patent<\/td><td>2030<\/td><td>2038<\/td><td>8 calendar years<\/td><\/tr><tr><td>Entresto<\/td><td>District decision to Federal Circuit<\/td><td>July 7, 2023<\/td><td>Jan. 10, 2025<\/td><td>553 days<\/td><\/tr><tr><td>Entresto<\/td><td>Pediatric exclusivity end to requested &#8216;918 bar<\/td><td>July 16, 2025<\/td><td>Nov. 9, 2026<\/td><td>481 days<\/td><\/tr><tr><td>Cabometyx<\/td><td>Release date to earliest MSN launch<\/td><td>Aug. 31, 2026<\/td><td>Jan. 15, 2030<\/td><td>1,233 days (about 3.4 years)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What a Failed Patent Challenge Means for Generic and Biosimilar Developers<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Read your competitor&#8217;s loss as a design brief. The claim construction states the boundary. The failed prior-art theories state what not to repeat. The product facts in the opinion show what a court will accept as proof.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Three practical steps follow from the four cases. First, list the claim terms the court defined and check your product against each one. Second, list the invalidity arguments that failed and decide whether you have different art or a different theory. Third, check which patents in the portfolio still stand after the ruling. In the Entresto record, the second patent changed the commercial result. In the Cabometyx record, a fourth patent sets the later window. This is analysis, not legal advice.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What a Failed Patent Challenge Means for Brand Manufacturers<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A brand company can read a rival&#8217;s failed challenge in the same way. The Eliquis and Entresto opinions show how courts treat particle-size limits and combination claims. A brand team that drafts claims in the same class can use that record. It can also use the record to find the weak point in its own claims.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Nuplazid case shows a portfolio lesson. The compound patent runs to 2030, but the formulation patents run to 2038. <a href=\"#ref4\">[4]<\/a> A team that expects the compound patent to carry the franchise should check whether later patents add more exclusivity than the original. The Tu and Lemley data show that secondary patents made up 89 percent of the valid patents in their sample. <a href=\"#ref5\">[5]<\/a> Analysis: that share fits the pattern in Nuplazid, where formulation patents extend the date.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What a Failed Patent Challenge Means for Investors, Forecasters, and Business Development Teams<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">An investor needs a date and a confidence level. The annual report for Eliquis gave conditional dates before the appeal. <a href=\"#ref3\">[3]<\/a> The Exelixis release gives an earliest launch date with explicit conditions. <a href=\"#ref8\">[8]<\/a> Both documents separate confirmed events from conditional ones.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Use three rules when you build a forecast from a failed challenge. Record the date as conditional until every appeal and every other asserted patent resolves. Record the settled generic dates apart from the unsettled challengers. Record which patent sets each date. The Entresto record shows why: the &#8216;659 ruling and the &#8216;918 patent point to different dates 481 days apart (analysis). <a href=\"#ref7\">[7]<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>When a Failed Challenge Misleads You<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>A Loss on Clear and Convincing Evidence Is Not a Strength Score<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The Supreme Court held in Microsoft Corp. v. i4i that &#8220;Section 282 requires an invalidity defense to be proved by clear and convincing evidence.&#8221; <a href=\"#ref17\">[17]<\/a> A challenger that loses may have failed to meet a high bar. It does not follow that the patent is strong. Analysis: a patent that survived one challenger&#8217;s evidence may fall to a different challenger with different art.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>A Ruling Binds the Parties Before the Court<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In Blonder-Tongue Laboratories v. University of Illinois Foundation, the Supreme Court allowed a defendant to plead estoppel against a patentee whose patent a court had declared invalid. <a href=\"#ref18\">[18]<\/a> Analysis: the sources I reviewed show no matching rule that stops a new challenger after a validity win. In Eliquis, Bristol-Myers Squibb settled with some filers and litigated against three. <a href=\"#ref2\">[2]<\/a> Each case involved named parties.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Dates Move After the Ruling<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Appeals, further patents, and regulatory exclusivities can change a date. The Exelixis release says the January 15, 2030 date is &#8220;subject to any additional appeals or regulatory exclusivity.&#8221; <a href=\"#ref8\">[8]<\/a> The Entresto timeline moved through an injunction fight, an FDA lawsuit, and a settlement within one year. <a href=\"#ref7\">[7]<\/a> Treat every date from a ruling as current status, not as a final fact.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How to Read a Failed Challenge: A Seven-Step Workflow<\/strong><\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Find the court opinion and the docket entry. Use the Federal Circuit opinion when one exists. For example, the Federal Circuit posts its Entresto opinion as a public PDF. <a href=\"#ref6\">[6]<\/a><\/li>\n\n\n\n<li>Build a date table. List each patent, its expiration, and any extension. Add the dates from the company&#8217;s SEC filing.<\/li>\n\n\n\n<li>Extract the claim constructions. Write each defined term in the court&#8217;s words.<\/li>\n\n\n\n<li>List each invalidity theory and mark it as failed, reversed, or not reached.<\/li>\n\n\n\n<li>Record any facts about the challenger&#8217;s product or process.<\/li>\n\n\n\n<li>Map the result to the full portfolio. Identify which patent sets each date.<\/li>\n\n\n\n<li>Log what stays open: appeals, other patents, other challengers, and regulatory exclusivities.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Keep the calculated figures apart from the reported ones. Label each calculation as analysis, as this article does.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Where DrugPatentWatch Fits<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">DrugPatentWatch aggregates Orange Book patents, expiration dates, and litigation records. That helps with Steps 1 and 2 of the workflow, because you can find the case and the patent list in one place. Use it to locate the records. Then confirm each fact in the court opinion, the SEC filing, or the USPTO record. A database tells you where to look. The primary document tells you what happened.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Key Takeaways<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>A failed patent challenge produces a public record of dates, claim meanings, failed arguments, and product facts.<\/li>\n\n\n\n<li>In Eliquis, the challengers&#8217; loss removed two of three scenarios in Bristol-Myers Squibb&#8217;s annual report and left April 1, 2028 for settled generics. <a href=\"#ref3\">[3]<\/a><\/li>\n\n\n\n<li>The two Eliquis launch dates in that report are 497 days apart (analysis).<\/li>\n\n\n\n<li>Nuplazid&#8217;s formulation patents run eight calendar years past its compound patent (analysis). <a href=\"#ref4\">[4]<\/a><\/li>\n\n\n\n<li>In Entresto, MSN lost every validity ground reviewed on the &#8216;659 patent, but the date was set by expiry, pediatric exclusivity, and a second patent. <a href=\"#ref6\">[6]<\/a> <a href=\"#ref7\">[7]<\/a><\/li>\n\n\n\n<li>In Cabometyx, the earliest MSN launch date is January 15, 2030, with a fourth patent in trial in November 2026. <a href=\"#ref8\">[8]<\/a><\/li>\n\n\n\n<li>About 26 percent of litigated Orange Book patents with validity rulings were invalidated in the Tu and Lemley sample. <a href=\"#ref5\">[5]<\/a><\/li>\n\n\n\n<li>A loss on clear and convincing evidence does not prove that a patent is strong. <a href=\"#ref17\">[17]<\/a><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>FAQ<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How is a failed challenge different from a settled one?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A failed challenge ends in a court ruling for the patent owner. A settlement ends without one. In Eliquis, Bristol-Myers Squibb settled with Mylan and Micro Labs and litigated against three other filers. <a href=\"#ref2\">[2]<\/a> Analysis: the readable opinions come from the litigated cases, while settlement terms stay mostly private.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Where can I find the court opinion and the company&#8217;s own statement?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The Federal Circuit posts its opinions as public PDFs at cafc.uscourts.gov, as the Entresto opinion shows. <a href=\"#ref6\">[6]<\/a> Companies file annual reports on SEC EDGAR, where Bristol-Myers Squibb&#8217;s FY2020 report states the Eliquis dates. <a href=\"#ref3\">[3]<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How much revenue sits inside the 497-day Eliquis gap?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The sources do not say. Bristol-Myers Squibb reported global Eliquis sales of $9.17 billion in 2020. <a href=\"#ref12\">[12]<\/a> The figure does not split U.S. sales, so the 497-day gap cannot be converted into U.S. revenue from these sources (analysis).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How long did the Eliquis appeal take?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The district court opinion is dated August 5, 2020. <a href=\"#ref1\">[1]<\/a> The Federal Circuit decided on September 3, 2021. <a href=\"#ref9\">[9]<\/a> The interval is 394 days (analysis).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>What should an investor look for in a 10-K when a patent case is on appeal?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Look for conditional launch dates. Bristol-Myers Squibb&#8217;s FY2020 report gave a different launch date for each possible appeal outcome. <a href=\"#ref3\">[3]<\/a> Record each outcome and its date, then check later filings for the result.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How many Orange Book IPR petitions were filed each year?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Schwarz and Fishwick report 10 petitions in 2013, 32 in 2014, 132 in fiscal year 2015, 127 in fiscal year 2016, 76 in fiscal year 2017, and 67 in fiscal year 2018. <a href=\"#ref10\">[10]<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Does prioritized examination (Track One) separate valid from invalid patents?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Not in the Tu and Lemley sample. Track One use was 59.6 percent for invalid patents and 60.3 percent for not-invalid patents, against 2.6 percent for a control group. <a href=\"#ref5\">[5]<\/a> Analysis: litigated patents used it far more than average patents, but it did not distinguish winners from losers.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How many companies challenge one drug at the same time?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The count varies. In Eliquis, the Federal Circuit caption lists four appellants: Sigmapharm, Sunshine Lake, HEC Pharm USA, and Unichem. <a href=\"#ref9\">[9]<\/a> Trade press reports two more filers, Mylan and Micro Labs, that settled. <a href=\"#ref2\">[2]<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Do continuation patents fare worse in challenges?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In the Tu and Lemley sample, continuation applications produced 73 percent of invalid patents, 60 percent of not-invalid patents, and 35 percent of the control group. <a href=\"#ref5\">[5]<\/a> Analysis: continuations appear more often among invalidated patents, but they also appear often among survivors.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>How large is the sample behind the 26 percent invalidation figure?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The study covers 328 cases and 632 patents. The invalid group has 82 cases and 142 patents. The not-invalid group has 196 cases and 404 patents. <a href=\"#ref5\">[5]<\/a> It includes only cases that reached a final decision, so settled disputes are absent.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>References<\/strong><\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Finnegan. (2021, September 27). Federal Circuit crystallizes BMS apixaban district court win. <em>IP-FDA Blog<\/em>. https:\/\/www.finnegan.com\/en\/insights\/blogs\/ip-fda-blog\/federal-circuit-crystallizes-bms-apixaban-district-court-win.html<\/li>\n\n\n\n<li>BioPharma Dive. (2020, August 6). Court ruling on Eliquis patents [News article]. https:\/\/www.biopharmadive.com\/news\/bristol-myers-pfizer-eliquis-patent-court-ruling\/583027\/<\/li>\n\n\n\n<li>Bristol-Myers Squibb Company. (2021). <em>Form 10-K for the fiscal year ended December 31, 2020<\/em>. U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/14272\/000001427221000066\/bmy-20201231.htm<\/li>\n\n\n\n<li>ACADIA Pharmaceuticals Inc. (2026). <em>Form 10-K for the fiscal year ended December 31, 2025<\/em>. U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/1070494\/000119312526072519\/acad-20251231.htm<\/li>\n\n\n\n<li>Tu, S. S., &amp; Lemley, M. A. (2022). What litigators can teach the patent office about pharmaceutical patents. <em>Washington University Law Review<\/em>. https:\/\/wustllawreview.org\/2022\/08\/19\/what-litigators-can-teach-the-patent-office-about-pharmaceutical-patents\/<\/li>\n\n\n\n<li>In re Entresto (Sacubitril\/Valsartan), Nos. 2023-2218, 2023-2220, 2023-2221 (Fed. Cir. Jan. 10, 2025). U.S. Court of Appeals for the Federal Circuit. https:\/\/cafc.uscourts.gov\/opinions-orders\/23-2218.OPINION.1-10-2025_2448627.pdf<\/li>\n\n\n\n<li>IPFray. (2025, June 17). Novartis and MSN settle part of chronic heart failure patent fight, but key patent remains. https:\/\/ipfray.com\/novartis-and-msn-settle-part-of-chronic-heart-failure-patent-fight-but-key-patent-remains\/<\/li>\n\n\n\n<li>Exelixis, Inc. (2026, August 31). Exelixis announces update on patent litigation trial appeal with MSN Laboratories [Press release]. https:\/\/ir.exelixis.com\/node\/27706<\/li>\n\n\n\n<li>Bristol-Myers Squibb Co. v. Sigmapharm Laboratories, LLC, Nos. 2020-2229, 2020-2252, 2020-2258 (Fed. Cir. Sept. 3, 2021). https:\/\/caselaw.findlaw.com\/court\/us-federal-circuit\/2143622.html<\/li>\n\n\n\n<li>Schwarz, C., &amp; Fishwick, L. (2019, January 23). PTAB trends: Orange Book patents surviving the &#8220;death squad.&#8221; <em>IPWatchdog<\/em>. https:\/\/ipwatchdog.com\/2019\/01\/23\/ptab-trends-orange-book-patents-surviving-death-squad\/<\/li>\n\n\n\n<li>Federal Trade Commission. (2002, October 9). Testimony on generic drug entry prior to patent expiration [Testimony]. https:\/\/www.ftc.gov\/node\/40929<\/li>\n\n\n\n<li>Fierce Pharma. (2021, September). Bristol Myers, Pfizer score another win in their Eliquis patent defense, protecting the blockbuster until 2028. https:\/\/www.fiercepharma.com\/pharma\/bristol-myers-pfizer-score-another-win-their-eliquis-defense-protecting-blockbuster<\/li>\n\n\n\n<li>Acadia Pharmaceuticals Inc. (2025, May 16). Delaware District Court rules in favor of Acadia on NUPLAZID [Press release]. https:\/\/acadia.com\/en-us\/media\/news-releases\/delaware-district-court-rules-favor-acadia-nuplazidr<\/li>\n\n\n\n<li>Acadia Pharmaceuticals Inc. (2025, June 9). U.S. Court of Appeals for the Federal Circuit affirms prior Delaware District Court rulings in favor of Acadia in NUPLAZID (pimavanserin) composition of matter patent [Press release]. Business Wire. https:\/\/www.businesswire.com\/news\/home\/20250609455203\/en\/U.S.-Court-of-Appeals-for-the-Federal-Circuit-Affirms-Prior-Delaware-District-Court-Rulings-in-Favor-of-Acadia-in-NUPLAZID-pimavanserin-Composition-of-Matter-Patent<\/li>\n\n\n\n<li>pharmaphorum. (2024, December). Novartis bid to block generic Entresto in US suffers setback. https:\/\/pharmaphorum.com\/news\/novartis-bid-block-generic-entresto-us-suffers-setback<\/li>\n\n\n\n<li>Fierce Pharma. (2024, August). Novartis loses bid to thwart launch of MSN&#8217;s Entresto generic, for now. https:\/\/www.fiercepharma.com\/pharma\/novartis-loses-bid-thwart-launch-msns-entresto-generic-now<\/li>\n\n\n\n<li>Microsoft Corp. v. i4i Ltd. Partnership, 564 U.S. 91 (2011). https:\/\/www.govinfo.gov\/content\/pkg\/USREPORTS-564\/pdf\/USREPORTS-564-91.pdf<\/li>\n\n\n\n<li>Blonder-Tongue Laboratories, Inc. v. University of Illinois Foundation, 402 U.S. 313 (1971). https:\/\/www.govinfo.gov\/content\/pkg\/USREPORTS-402\/pdf\/USREPORTS-402-313.pdf<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>On August 5, 2020, a federal judge in Delaware held that two patents on Eliquis (apixaban) were valid and infringed [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":40098,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-40095","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/40095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=40095"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/40095\/revisions"}],"predecessor-version":[{"id":40099,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/40095\/revisions\/40099"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/40098"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=40095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=40095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=40095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}